Swiss National Bank Boosts Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Swiss National Bank raised its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 15.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 76,200 shares of the company’s stock after buying an additional 10,300 shares during the quarter. Swiss National Bank’s holdings in Kymera Therapeutics were worth $3,066,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of KYMR. Wellington Management Group LLP raised its stake in shares of Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after acquiring an additional 308,954 shares in the last quarter. FMR LLC increased its position in shares of Kymera Therapeutics by 5.8% during the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after purchasing an additional 282,301 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after purchasing an additional 95,547 shares during the last quarter. Cinctive Capital Management LP acquired a new stake in shares of Kymera Therapeutics in the 3rd quarter worth $2,688,000. Finally, Eventide Asset Management LLC grew its stake in Kymera Therapeutics by 9.9% during the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock worth $24,039,000 after buying an additional 45,803 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright increased their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Citigroup began coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. Stephens reiterated an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, BMO Capital Markets began coverage on Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Stock Down 4.5 %

Kymera Therapeutics stock opened at $30.39 on Thursday. Kymera Therapeutics, Inc. has a 52 week low of $29.07 and a 52 week high of $53.27. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -12.99 and a beta of 2.22. The business’s 50-day moving average price is $36.29 and its 200 day moving average price is $42.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,788 shares of company stock worth $455,202. Company insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.